SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Mynaric AG (MYNA) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+1422.1%).
- Analyst consensus target $4.00 (+1422.1% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 34/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — MYNA
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio1.18
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-3.87
Book Value / Share$0.00
Revenue / Share$0.22
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$4.00 (+1422.1%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2014 |
$0.00 |
$1.3M |
$-195.83K |
-15.1% |
| 2015 |
$-0.08 |
$1.86M |
$-840.78K |
-45.3% |
| 2016 |
$-0.16 |
$471.5K |
$-1.84M |
-390.9% |
| 2017 |
$-0.64 |
$2.93M |
$-6.92M |
-236.3% |
| 2018 |
$-0.72 |
$4.52M |
$-7.78M |
-172.2% |
| 2019 |
$-0.85 |
$114K |
$-9.9M |
-8680.7% |
| 2020 |
$-1.54 |
$679K |
$-20.64M |
-3040.1% |
| 2021 |
$-2.67 |
$2.36M |
$-45.48M |
-1931.1% |
| 2022 |
$-3.39 |
$4.42M |
$-73.78M |
-1668.5% |
| 2023 |
$-3.87 |
$5.39M |
$-93.53M |
-1735.2% |
